# Dimethyl Fumarate in Adrenomyeloneuropathy

> **NCT06513533** · PHASE2,PHASE3 · RECRUITING · sponsor: **Pujol, Aurora, M.D.** · enrollment: 40 (estimated)

## Conditions studied

- Adrenomyeloneuropathy Without Cerebral Involvement

## Interventions

- **OTHER:** Placebo
- **DRUG:** Dimethyl fumarate

## Key facts

- **NCT ID:** NCT06513533
- **Lead sponsor:** Pujol, Aurora, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-23
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513533, "Dimethyl Fumarate in Adrenomyeloneuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06513533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*